Ratio Therapeutics Raises $70 Million to Advance Radiotherapeutics
BOSTON, July 31, 2026 Ratio Therapeutics announced the successful closing of a $70 million Series C financing, increasing the...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BOSTON, July 31, 2026 Ratio Therapeutics announced the successful closing of a $70 million Series C financing, increasing the...
CAMBRIDGE, UK, July 22, 2026 Healx, an AI-powered clinical-stage biotechnology company, has announced that the first patient has been...
LEXINGTON, Mass., July 17, 2026 Agenus Inc. announced that three investigator-sponsored studies evaluating its investigational botensilimab plus balstilimab (BOT+BAL)...
CAMBRIDGE, UK, May 22, 2026 STORM Therapeutics announced that new Phase 1 data for its first-in-class METTL3 inhibitor STC-15...
